Inventor
RAVI JAGASIA
Inventor
CH
Overview
Patents· 9 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
G01NInvestigating or analysing materials by determining their chemical or physical properties23%
A61KPreparations for medical, dental or toiletry purposes19%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
PatentTitleYear
12,596,118Oligonucleotides for inducing paternal UBE3A expression202612,566,172Oligonucleotides for inducing paternal UBE3A expression202612,360,123E3 ubiquitin ligase (UBE3A) protein targets202512,259,380Oligonucleotides for inducing paternal UBE3A expression202512,203,071Oligonucleotide agonists targeting progranulin202512,104,153Antisense oligonucleotide for targeting progranulin202412,084,657Oligonucleotides targeting RNA binding protein sites202411,852,627Oligonucleotides for inducing paternal UBE3A expression202311,320,421Oligonucleotides for inducing paternal UBE3A expression2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to HOFFMANN LA ROCHE (8)· patent assignee history
2022–2026Based in CH· patent location history
2026Patents assigned to HOFFMANN LA ROCHE INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HOFFMANN LA ROCHE | 8 | 2022–2026 |
| HOFFMANN LA ROCHE INC | 1 | 2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| CH | 9 | 2022–2026 |